on BioVersys AG
BioVersys and Hackensack Meridian Health Collaborate on NTM Research
BioVersys AG has announced a strategic collaboration with Hackensack Meridian Health (HMH) to enhance its Ansamycin Chemistry platform and research into non-tuberculous mycobacteria (NTM) diseases. This exclusive agreement aims to develop ansamycin antimicrobial candidates into viable treatments.
HMH, a leading healthcare network in the US, will contribute its expertise through its Center for Discovery and Innovation. NTMs are a significant concern, particularly for patients with chronic lung conditions like cystic fibrosis. BioVersys aims to address these challenges by leveraging advanced lead molecules and building on its existing research efforts.
The collaboration will involve shared development of ansamycin candidates, with HMH receiving upfront payments and potential royalties. This partnership underscores BioVersys' commitment to advancing novel antibacterial treatments for life-threatening infections.
R. H.
Copyright © 2026 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all BioVersys AG news